ACKR2 inhibition may also be effective in the development of novel treatment strategies for GVHD patients, particularly steroid-resistant patients, that depend on the transfer and/or increase of immunosuppressive and regulatory leukocyte populations. This evidence concerns the gene ACKR2 and graft versus host disease.